New Delhi, Mar 12: Domestic pharma giant Ranbaxy Laboratories Ltd (RLL) today announced the launch of its brand Forzest (TADALAFIL), the most recently approved prescription medicine for the treatment of Erectile Dysfunction (ED) in men, in India.
At present, the available oral specific medication for management of ED is Sildenafil with a Rs 70-crore market in the country.
Forzest has an advantage over Sildenafil in terms of longer therapeutic window as it acts faster and more importantly can be taken any time up to 36 hours in advance, the city-based drugmaker added.
''Introduction of Forzest will provide Indian doctors with best-in-class and contemporary therapeutic option for management of Erectile Dysfunction, which also gives greater time window to the patients,'' Ranbaxy regional director (India operations) Sanjeev I Dani said.
Erectile Dysfunction is a seriously under-diagnosed condition, which largely goes untreated due to embarrassment of patients. It is estimated that about 150 million people suffer from ED and about nine out of every ten men do not seek treatment.
In India, it is estimated that about 50 million patients suffer from ED. Studies also indicate that men with diabetes have three-fold higher incidence of ED and 50 per cent of them develop the condition within 10 years of being diagnosed with diabetes. Bureau Report